Ken Griffin’s Processa Pharmaceuticals PCSA Stock Holding History

Ken Griffin’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-631	Closed	-$106K	–	15255
2023 Q4	$106K	Buy	631 +299	+90%	+$66.7K	﹤0.01%	10865
2023 Q3	$42.4K	Sell	332 -234	-41%	-$44.2K	﹤0.01%	11941
2023 Q2	$141K	Buy	+566	New	+$167K	﹤0.01%	10424
2021 Q3	–	Sell	-20	Closed	-$83K	–	14432
2021 Q2	$83K	Sell	20 -6	-23%	-$23.2K	﹤0.01%	13055
2021 Q1	$143K	Buy	+26	New	+$121K	﹤0.01%	12104

Other funds holding PCSA

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MSG

Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

MIM

Macroview Investment Management Bethesda, Maryland $162M AUM 22.52% 1-Year Est. Return

Ken Griffin's PCSA Position: Q1 2024 in Review

Ken Griffin sold out of Processa Pharmaceuticals (PCSA) in Q1 2024, closing a stake of 631 shares — an estimated $106K sold.

Ken Griffin first reported a position in PCSA in Q1 2021 and held it in 5 quarters. The position peaked at $143K in Q1 2021. 9 funds tracked by Wall St. Rank hold PCSA as of Q1 2024.

Ken Griffin reported no remaining Processa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Ken Griffin sold 631 Processa Pharmaceuticals shares in Q1 2024, an estimated $106K.
Ken Griffin first reported a position in Processa Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Ken Griffin's Processa Pharmaceuticals position peaked at $143K in Q1 2021.
9 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.